Formycon AG

Formycon AG

FYB ·

Formycon AG (FYB) is a Medical pharmaceuticals company in the Healthcare sector, listed on Deutsche Borse Xetra. This page provides the complete earnings calendar, dividend schedule, and financial data for Formycon AG in 2026. The next earnings report is expected on April 29, 2027.

Earnings calendar

Next earnings date

29 Apr 2027

In 252 days

EPS estimate

—

Revenue estimate

—

Past earnings

12 Aug 2026
EPS actual
-0.95
estimate -0.69
Revenue actual
29.5M
estimate 41.7M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
23 Jun 2026
EPS actual
-0.69 (0.0%)
estimate -0.69
Revenue actual
41.7M (0.0%)
estimate 41.7M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
22 Apr 2026
EPS actual
-0.69 (0.0%)
estimate -0.69
Revenue actual
41.7M (0.0%)
estimate 41.7M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Formycon AG missed consensus estimates in its latest earnings report, with EPS of USD -0.9479 missing the estimate of USD -0.693 and revenue of USD 29.47 million falling 29.3% short of the USD 41.7 million expected. In the previous report, both EPS and revenue met expectations.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

Sector
Healthcare
Industry
Medical pharmaceuticals
Country
Germany
Exchange
Deutsche Borse Xetra
CEO
Stefan Glombitza
Employees
250
IPO date
29 Jan 2018
ISIN
DE000A1EWVY8
Website
formycon.com

Frequently asked questions

When does Formycon AG (FYB) next report earnings?

Formycon AG (FYB) is scheduled to report earnings on April 29, 2027.

What was Formycon AG's most recent earnings date?

Formycon AG (FYB) last reported earnings on August 12, 2026.

Where is Formycon AG stock listed?

Formycon AG (FYB) is listed on Deutsche Borse Xetra.